Clinical Trial COGAALL0631


A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy =/+ FLT3 Inhibition

Principal Investigator(s)

Haydar Frangoul


  • Protocol No. COGAALL0631
  • Open Date: 09/09/2008
  • Staging: Phase III
  • Age Group: Children
  • Scope: National
  • Objective: To compare the 3-year event-free survival (EFS) of infants with MLL-R ALL randomized to treatment with a modified P9407 chemotherapy backbone with or without the FLT3 inhibitor lestaurtinib.
  • Disease Sites: Pediatrics; Leukemia
  • Therapies: None Specified
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00557193
  • Secondary Protocol No: AALL0631



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.